Subluxation

PainTEQ Receives Two New Patents for the LinQ Procedure, Advancing Treatments for SI Joint Dysfunction

Retrieved on: 
Thursday, May 2, 2024
Sacroiliac joint, LinQ, Subluxation, Pharmaceutical industry

These patents mark a notable step forward in medical device innovation, offering new hope to thousands suffering from debilitating lower back pain.

Key Points: 
  • These patents mark a notable step forward in medical device innovation, offering new hope to thousands suffering from debilitating lower back pain.
  • "With these two new patents plus the three patents granted in 2023, PainTEQ now boasts a total of 14 patents.
  • This portfolio underscores PainTEQ's commitment to advancing treatments for sacroiliac joint pain," said Sean LaNeve, CEO of PainTEQ.
  • US patent number 11,963,883 (April 23, 2024) relates to the design of the LinQ allograft implant for the sacroiliac joint.

PainTEQ Announces Successful Completion of First In-Office LinQ Procedure Under New CMS Billing Code

Retrieved on: 
Thursday, January 18, 2024
Physician, Medicare, Sacroiliac joint dysfunction, Subluxation, Patient, LinQ, CMS, Safety, MD, Hospital

The patient who underwent the LinQ procedure experienced a quick and comfortable recovery, highlighting the procedure's efficiency and the benefits of an in-office setting.

Key Points: 
  • The patient who underwent the LinQ procedure experienced a quick and comfortable recovery, highlighting the procedure's efficiency and the benefits of an in-office setting.
  • The patient's positive feedback on the ease and convenience of the procedure underscores its potential to transform SI joint dysfunction treatment.
  • PainTEQ CEO Sean LaNeve added, "This is a groundbreaking moment for PainTEQ and for patients suffering from SI joint dysfunction.
  • The LinQ procedure, developed by PainTEQ, represents a major advancement in the treatment of SI joint dysfunction.

The Ehlers-Danlos Society Receives $6.7 Million from the Mike and Sofia Segal Foundation to Advance Cutting-Edge Research for Ehlers-Danlos Syndrome

Retrieved on: 
Wednesday, December 20, 2023
Leukemia, Ehlers-Danlos Society, Quality of life, Partnership, Chronic myelomonocytic leukemia, Rupture, Research, Bone marrow, Pain, Blood, Tissue, CMML, Cardiovascular disease, EDS, Society, Subluxation, Ehlers–Danlos syndromes, Joint, Dislocation, HSD, Bruise, Diagnosis, Injury, Child

NEW YORK, Dec. 20, 2023 /PRNewswire/ -- The Ehlers-Danlos Society, the global non-profit dedicated to advancing and accelerating research in the Ehlers-Danlos syndromes (EDS) and hypermobility spectrum disorders (HSD), today announced it has received a $6.7 million funding commitment from the Mike and Sofia Segal Foundation (the "Foundation") to advance its groundbreaking research initiatives.

Key Points: 
  • The support from the Mike and Sofia Segal Foundation is invaluable in propelling our research towards earlier diagnosis.
  • In 1978, Mike and Sofia Segal arrived in the U.S. from present-day Ukraine with $120, a young child, and just two suitcases.
  • The partnership between the Ehlers-Danlos Society and the Foundation marks a significant leap forward in the quest for breakthroughs in EDS and HSD research.
  • The Ehlers-Danlos Society and the Foundation hope this investment will serve as a catalyst, inspiring related contributions and collaborations within the scientific community and beyond.

REGENATIVE LABS, TOGETHER WITH THE PAIN AND SLEEP THERAPY CENTER, PUBLISHES CASE STUDY DEMONSTRATING NEW CARE ADVANCEMENTS USING WHARTON'S JELLY ALLOGRAFTS IN TEMPOROMANDIBULAR JOINT DEFECTS

Retrieved on: 
Thursday, October 26, 2023
Temporomandibular joint, Mouth, Physician, Head, Osteoarthritis, Pathology, Temporomandibular joint dysfunction, Publication, Umbilical cord, Injection, Massage, Research, PRF, Wharton's jelly, Reynolds, Subluxation, Medicine, NP, Patient, Muscular system, TMD, Today, Dentistry, Medical imaging, Nursing, Veterinary medicine, Jelly, Pain, TMJ, Regenerative medicine

PENSACOLA, Fla., Oct. 26, 2023 /PRNewswire/ -- Regenative Labs (Regenative), a leading HCT/P manufacturer, announces the publication of a case study demonstrating new care advancements using its Wharton's Jelly allografts in the supplementation of Temporomandibular Joint (TMJ) defects. The case study titled "Single-Center Retrospective Study of Flowable Umbilical Cord Tissue Allograft Application in Temporomandibular Joint Defects: An Investigative Study," was published by Walsh Medical Media and can be accessed in its entirety here.

Key Points: 
  • PENSACOLA, Fla., Oct. 26, 2023 /PRNewswire/ -- Regenative Labs (Regenative), a leading HCT/P manufacturer, announces the publication of a case study demonstrating new care advancements using its Wharton's Jelly allografts in the supplementation of Temporomandibular Joint (TMJ) defects.
  • The case study titled "Single-Center Retrospective Study of Flowable Umbilical Cord Tissue Allograft Application in Temporomandibular Joint Defects: An Investigative Study," was published by Walsh Medical Media and can be accessed in its entirety here.
  • After one application of Regenative's Wharton's Jelly allograft, the patient's pain improved by an average of 75% after 90 days.
  • "A few years ago, we started using PRF (platelet-rich fibrin) therapy in the jaw joint, and we thought that was revolutionary.

REGENATIVE LABS, TOGETHER WITH THE PAIN AND SLEEP THERAPY CENTER, ANNOUNCE NEW CARE ADVANCEMENTS USING WHARTON'S JELLY ALLOGRAFTS IN TEMPOROMANDIBULAR JOINT DEFECTS

Retrieved on: 
Tuesday, October 3, 2023
Injection, TMD, Muscular system, Umbilical cord, Physician, Pathology, Head, Osteoarthritis, Research, Medicine, Reynolds, Today, Massage, Temporomandibular joint, PRF, Publication, Patient, Temporomandibular joint dysfunction, Wharton's jelly, NP, Subluxation, Mouth, Dentistry, Medical imaging, Nursing, Veterinary medicine, Regenerative medicine, Jelly, TMJ, Pain

PENSACOLA, Fla., Oct. 3, 2023 /PRNewswire/ -- Regenative Labs (Regenative), a leading HCT/P manufacturer, announces a retrospective case series demonstrating new care advancements using its Wharton's Jelly allografts in the supplementation of Temporomandibular Joint (TMJ) defects.

Key Points: 
  • PENSACOLA, Fla., Oct. 3, 2023 /PRNewswire/ -- Regenative Labs (Regenative), a leading HCT/P manufacturer, announces a retrospective case series demonstrating new care advancements using its Wharton's Jelly allografts in the supplementation of Temporomandibular Joint (TMJ) defects.
  • Standard treatment includes simply resting the jaw muscles and avoiding use, massage, physical therapy, medication management, and, when all else fails, surgery.
  • After one application of Regenative's Wharton's Jelly allograft, the patient's pain improved by an average of 75% after 90 days.
  • "A few years ago, we started using PRF (platelet-rich fibrin) therapy in the jaw joint, and we thought that was revolutionary.

PainTEQ Launches World's First Surgery-Ready Instruments for Posterior Approach with LinQ

Retrieved on: 
Wednesday, September 6, 2023
Tissue, SI, Partnership, University, Bleeding, Kowsar Publishing, Anesthesiology, LinQ, Carbon, Subluxation, CCO, University of Kansas Health System, MD, Patient, Physician, Safety, Decorticator, Dentistry

TAMPA, Fla., Sept. 6, 2023 /PRNewswire/ -- PainTEQ, a leading innovator in minimally invasive sacroiliac (SI) joint dysfunction treatments, announced the release of its new Surgery-Ready Instrument set, a major advancement in the field of SI joint fusion surgery. This third-generation surgical instrument set for PainTEQ's LinQ procedure includes single-use, surgery-ready instruments, offering a safer and more cost-effective option for interventional pain physicians. "PainTEQ's commitment to improving patient outcomes has been the driving force behind our innovation," said Sean LaNeve, CEO of PainTEQ.

Key Points: 
  • Designed from physician feedback, the new instruments offer single-use, surgery-ready instruments for a safer, efficient, and environmentally friendly solution.
  • This third-generation surgical instrument set for PainTEQ's LinQ procedure includes single-use, surgery-ready instruments, offering a safer and more cost-effective option for interventional pain physicians.
  • "PainTEQ's commitment to improving patient outcomes has been the driving force behind our innovation," said Sean LaNeve, CEO of PainTEQ.
  • "I was honored to work with the PainTEQ R&D team to help develop these surgery-ready instruments.

Dr. Thomas Yarbrough Joins PetVivo Holdings, Inc. as the Senior Research Director

Retrieved on: 
Monday, June 5, 2023
Osteoarthritis, Human, Therapy, Arthralgia, Regeneration, Abnormality, Research, Subluxation, Athlete, Animal, Chondrocyte, Patient, Center for Tissue Regeneration and Engineering at Dayton, Biology, Robotics, Medical device

He began his career developing a referral base while working in research under the esteemed Dr. Hari Reddi at the Center for Tissue Regeneration and repair at the UC Medical center.

Key Points: 
  • He began his career developing a referral base while working in research under the esteemed Dr. Hari Reddi at the Center for Tissue Regeneration and repair at the UC Medical center.
  • Throughout his career he has stayed peripherally involved in research both from the bench-top to the clinic.
  • Although varied in scope his primary research interests and passion has always involved the arena of management of osteoarthritis.
  • Colleagues that know him know he is an open skeptic very slow to follow the new trends that frequent the veterinary space.

PainTEQ Ranked #149 on the Inc. 5000 List of Fastest-Growing Private Companies in America

Retrieved on: 
Friday, August 26, 2022
Chronic pain, Subluxation, Durability, SIJ, LinQ, Physician, SI, Pain management, Multimedia, Inc. (magazine), Growth, Patient, Airline, Dentistry, Tampa Bay, Safety

TAMPA, Fla., Aug. 26, 2022 /PRNewswire/ -- Prominent business magazine Inc. listed Tampa-based medical innovation company PainTEQ as #149 in their annual Inc. 5000 ranking of America's fastest-growing private companies.

Key Points: 
  • TAMPA, Fla., Aug. 26, 2022 /PRNewswire/ -- Prominent business magazine Inc. listed Tampa-based medical innovation company PainTEQ as #149 in their annual Inc. 5000 ranking of America's fastest-growing private companies.
  • This is the third consecutive year that PainTEQ has been included on the Inc. 5000 list, which is widely considered to be one of the most prestigious honors for high-performing businesses in the country.
  • About Inc. 5000: The Inc. 5000, through good times and challenging times, represents nearly 40 years of exceptional American growth stories.
  • Every year, Inc. Magazine ranks the top 5000 "fastest-growing private companies in America."

PetVivo, makers of Spryng™ with OsteoCushion™ Technology, introduces new Q&A sessions with equine expert Dr. Tracy Turner

Retrieved on: 
Wednesday, June 1, 2022
Tokyo, DVM, Faculty, Rehabilitation, Infection, Arthropathy, Company, Limp, Surgery, Cartilage, University, Animal, American Academy, American College, Subluxation, American College of Veterinary Surgeons, Therapy, Joint, Q&A, Sale, LAME, Method, GLOBE, Horse, FEI, Elective surgery, United States Equestrian Federation, FEI World Equestrian Games, Colorado State University, NASDAQ, Diagnosis, Arthralgia, Osteoarthritis, Diplomate of National Board, Veterinary medicine, Sports medicine, Pan American Games, Medical device, Dentistry

I told the owner she was likely at the end of her career, but that we could try injecting this new product," recounts Dr. Turner, owner of Turner Equine Sports Medicine and Surgery.

Key Points: 
  • I told the owner she was likely at the end of her career, but that we could try injecting this new product," recounts Dr. Turner, owner of Turner Equine Sports Medicine and Surgery.
  • "When I came back two weeks later, I didn't believe I was looking at the same horse she was 100% sound.
  • "Anti-inflammatories eliminate the inflammatory process, but they don't address the consequences of that," says Dr. Turner.
  • For more information about PetVivo Holdings, Inc. and our revolutionary product, SpryngTM with OsteoCushionTM Technology, please contact [email protected] or visit https://petvivo.com/ .

Tampa-Based Medical Device Company, PainTEQ, Treats Employee's Father With 100% Pain Relief 3-Months Post-Op

Retrieved on: 
Tuesday, April 5, 2022
Well, Multimedia, SI, Pain, Pain management, MD, Low back pain, Joint, Chronic pain, Subluxation, Physician, LinQ, Sport, Baseball, Patient, Dentistry

TAMPA, Fla., April 5, 2022 /PRNewswire/ -- It's not every day that you hear about a business practicing what they preach, but Tampa-based medical device company, PainTEQ, does just that. Their newly patented LinQ SI Joint Stabilization System was designed to alleviate chronic pain associated with sacroiliac (SI) joint dysfunction. When Robert Faxon, the father of Devin Faxon, one of PainTEQ's employees, experienced chronic SI joint pain, he knew exactly where to go for treatment.

Key Points: 
  • Their newly patented LinQ SI Joint Stabilization System was designed to alleviate chronic pain associated with sacroiliac (SI) joint dysfunction.
  • When Robert Faxon, the father of Devin Faxon, one of PainTEQ's employees, experienced chronic SI joint pain, he knew exactly where to go for treatment.
  • Working at PainTEQ, Devin was able to help his father schedule an appointment with Stephen Pyles, MD, of Pain Treatment Centers, Ocala, FL.
  • After a relatively short time in the operating room, Devin's father woke up and reported a significant reduction in pain.